Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

18.2%

2 terminated/withdrawn out of 11 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

6(54.5%)

Phase 1

5(45.5%)

11Total

Phase 2(6)

Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT05467800Phase 2Active Not Recruiting

Study of Canakinumab in Patients With Myelofibrosis

Role: lead

NCT07447817Phase 2Not Yet Recruiting

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Role: lead

NCT04281498Phase 2Completed

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Role: lead

NCT01693601Phase 1Completed

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Role: lead

NCT03895112Phase 1Completed

MPN-RC 118 AVID200 in Myelofibrosis

Role: lead

NCT03065400Phase 2Completed

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Role: lead

NCT02407080Phase 1Completed

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Role: lead

NCT01790295Phase 2Terminated

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Role: lead

NCT02076191Phase 1Completed

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Role: lead

NCT00572897Phase 2Completed

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Role: lead

NCT01291784Phase 1Terminated

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Role: lead

All 11 trials loaded